101. Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane plus platinum regimens
- Author
-
Ali Osman Kaya, Mustafa Dikilitas, Seçil Özkan, Ugur Coskun, Banu Ozturk, Emel Yaman, Mustafa Benekli, Ramazan Yildiz, Aytug Uner, Deniz Yamac, and Suleyman Buyukberber
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Paclitaxel ,Nausea ,medicine.medical_treatment ,Docetaxel ,Neutropenia ,Deoxycytidine ,Carboplatin ,chemistry.chemical_compound ,Internal medicine ,Carcinoma, Non-Small-Cell Lung ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Mucositis ,Humans ,Lung cancer ,Retrospective Studies ,Chemotherapy ,Taxane ,business.industry ,Hematology ,General Medicine ,medicine.disease ,Gemcitabine ,chemistry ,Taxoids ,medicine.symptom ,Cisplatin ,business ,medicine.drug - Abstract
In this study, we investigated the activity of single agent gemcitabine in the second-line setting of non-small cell lung cancer (NSCLC). File records of 21 patients treated with single agent gemcitabine in advanced NSCLC who received one prior chemotherapy including a taxane and platinum combination were retrospectively evaluated. Treatment consisted of IV gemcitabine 1,250 mg/m(2) on days 1 and 8, followed by a 1-week rest repeated every 3 weeks. A partial response was achieved in four (19%) patients. The median response duration was 16 (range, 12-32) weeks. Six (29%) patients had a SD more than 3 months. The median time to progression was 16 (range, 8-32) weeks. No complete response was observed. Median overall survival was 36 weeks for second-line gemcitabine in all patients (95%: CI 5-13 months). Hematological toxicity (all grades) was reported by 9 (42.9%) patients. One (4.75%) patient experienced grade 3/4 neutropenia. Grade 3/4 nausea and vomiting and mucositis were reported in one (4.75%) patient. In conclusion, this study shows that single agent gemcitabine is active and well tolerated as a second-line therapy for advanced NSCLC.
- Published
- 2008